Net Sales are expected to increase by 8.1 percent Q-o-Q (up 5.8 percent Y-o-Y) to Rs 542 crore, according to Centrum.
We expect Pfizer to report revenue growth of 6% YoY and 8% QoQ to Rs5.42bn. Pfizer’s flagship brands, namely, Minipress XL, Mucaine, Wysolone, Corex-Dx, Autrin and Prevenar 13 are likely to report double-digit growth during the quarter.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.